{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_risankizumab",
          "name": "Risankizumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 4
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_risankizumab",
          "type": "Drug",
          "label": "Risankizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised Pustular Psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_acitretin",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知对类似表型有效"
        },
        {
          "source": "drug_cyclosporine",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "临床证据支持"
        },
        {
          "source": "drug_methotrexate",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "用于其他类型银屑病，具有潜在效应"
        },
        {
          "source": "drug_infliximab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "靶向抗体，有证据显示效果良好"
        },
        {
          "source": "drug_adalimumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "抗体类药物在相似表型中表现出效用"
        },
        {
          "source": "drug_etanercept",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "已在临床试验中展示相关性"
        },
        {
          "source": "drug_ustekinumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "新型靶向治疗，报告疗效"
        },
        {
          "source": "drug_secukinumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "靶向IL-17，有潜在应用"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "临床显示良好，针对IL-23"
        },
        {
          "source": "drug_risankizumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "相似机制药物的持续研究"
        },
        {
          "source": "drug_brodalumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "基于IL-17作用，具备潜力"
        },
        {
          "source": "drug_apremilast",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.45,
          "agent": "Proponent",
          "rationale": "小分子，具有其他类型鳞屑病的疗效可能"
        }
      ],
      "merge": [],
      "set_weights": []
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多种药物显示对一般性脓疱型银屑病的支持证据",
        "confidence": "high"
      }
    ],
    "assumptions": [
      "所有药物的给药途径和靶器官到达性在临床上可接受"
    ],
    "uncertainties": [
      "不同药物效果因个体差异表现不一（需后续验证）"
    ],
    "next_focus_for_pi": [
      "是否需要考虑对每种药物的长期效果进行评估？"
    ]
  }
}